Promethazine Hci Injection
Product Images NDC 51662-1247
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Promethazine Hci (NDC 51662-1247). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hf Acquisition Co. Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Serialized Label On Vial (51662 1247 1 Promethazine HCl Injection Serialized Label On Vial)
51662124727 Promethazine Pouch Label
PROMETHAZINE HCI INJECTION, USP 25mg/mL 1mL is a medication for deep intramuscular or intravenous use. Its usual dosage is available in the package insert. It is recommended to keep it covered in the carton to protect it from light. The recommended storage temperature is 20°C-25°C (68°-77°F). The manufacturer’s package insert provides additional information. The medication is manufactured by HF Acquisition Co., LLC, located in Mukilteo, WA. The information includes NDC (51662-1247-2), LOT, EXP, and RXONLY.*
51662124734 Promethazine Case Label
PROMETHAZINE HCI INJECTION, USP 25mg/mL 1mL is a prescription drug used for deep intramuscular or intravenous use. It has an NDC code of 51662-1247-3, LOT number of 12345, and an expiration date of 2030-01-01. The usual dosage must be confirmed by checking the package insert. It should be kept protected from light and stored at a controlled room temperature. The manufacturer's package insert should be referred. It is manufactured by HF Acquisition Co., LLC with an original NDC code of 0641-0928-25.*
51662124734 Promethazine Rfid Label
Boxed Warning (Boxed Warning)
This is a warning that Promethazine hydrochloride injection is not safe for use in children under 2 years of age due to the risk of fatal respiratory depression. It can cause severe chemical irritation and tissue damage, leading to burning, pain, thrombophlebitis, tissue necrosis, and gangrene. Intramuscular injection is preferred over intravenous injection, and subcutaneous injection is not recommended. This text provides important information on administration and warnings for this medication.*
Logo (Logo)
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.